Comera Life Sciences Holdings, Inc. is a pre-clinical biotechnology company. The Company is engaged in developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience. Its proprietary formulation platform, SQore, is designed to transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self-administer in a single dose. The platform optimizes current versions of subcutaneous biologics and produce biosimilar versions of existing subcutaneous products. It has the potential for broad applications in therapeutic areas dependent on protein-based biologic treatments. The SQore platform includes proprietary structural calculations combined with analytical measurements to guide the selection of excipients for a given protein. The Company’s product programs: CLS-001, a preclinical stage biobetter for Crohn’s and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications.
No valuation ratios available.
No company officers listed.
During the most recent quarter, 201K shares were bought in insider trading.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.